Photo of Cesar M. Castro,  MD, MMSc

Cesar M. Castro, MD, MMSc

Massachusetts General Hospital

Massachusetts General Hospital


cmcastro@partners.org

Cesar M. Castro, MD, MMSc

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Assistant Professor, Medicine, Harvard Medical School
  • Assistant in Medicine, Medicine, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

My research endeavors seek to bridge advances in novel technologies and therapeutics with current clinical oncology needs. Prior formal intensive training in biomedical research design at the UC Berkeley School of Public Health and at the National Institutes of Health places me in a unique position to translate advances in the lab to the bedside. Moreover, I have broadened my skill set in clinical investigation by completing the Scholars in Clinical Science Program, a two year structured training curriculum that led to a Master of Medical Sciences from Harvard Medical School. I also completed a clinical fellowship in Oncology through the Dana-Farber / Partners Cancer Care Program. This breadth of clinical training exposed me to the day to day quandaries across the spectrum of solid and hematological tumors. Previously, I was involved with nanotechnology research at the National Cancer Institute where I truly first appreciated the meaning of interdisciplinary. I continue the spirit of this approach as Director of the Cancer Program within the MGH Center for Systems Biology. I am now poised to ask further challenging clinical questions in need of innovative solutions. My objectives are to refine and translate novel molecular imaging and nanosensing tactics into solid tumors. My efforts have led to inroads into point-of-care diagnostic solutions for resource-constrained regions globally. My daily research interactions involve an amalgam of chemists, material scientists, engineers, and clinicians as we continue to strive for interdisciplinary, innovative solutions to tackle biological problems plaguing cancer researchers.

Publications

Powered by Harvard Catalyst
  • Penson RT, Sales E, Sullivan L, Borger DR, Krasner CN, Goodman AK, Del Carmen MG, Growdon WB, Schorge JO, Boruta DM, Castro CM, Dizon DS, Birrer MJ. A SNaPshot of potentially personalized care: Molecular diagnostics in gynecologic cancer. Gynecol Oncol 2016; 141:108-12. PubMed
  • Jeong S, Park J, Pathania D, Castro CM, Weissleder R, Lee H. Integrated Magneto-Electrochemical Sensor for Exosome Analysis. ACS Nano 2016; 10:1802-9. PubMed
  • Sosulski A, Horn H, Zhang L, Coletti C, Vathipadiekal V, Castro CM, Birrer MJ, Nagano O, Saya H, Lage K, Donahoe PK, Pépin D. CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis. PLoS ONE 2016; 11:e0156595. PubMed
  • Pépin D, Sosulski A, Zhang L, Wang D, Vathipadiekal V, Hendren K, Coletti CM, Yu A, Castro CM, Birrer MJ, Gao G, Donahoe PK. AAV9 delivering a modified human Mullerian inhibiting substance as a gene therapy in patient-derived xenografts of ovarian cancer. Proc Natl Acad Sci U S A 2015; 112:E4418-27. PubMed
  • Im H, Shao H, Weissleder R, Castro CM, Lee H. Nano-plasmonic exosome diagnostics. Expert Rev Mol Diagn 2015; 15:725-33. PubMed
  • Castro CM, Im H, Le C, Lee H, Weissleder R, Birrer MJ. Exploring alternative ovarian cancer biomarkers using innovative nanotechnology strategies. Cancer Metastasis Rev 2015; 34:75-82. PubMed
  • Turetsky A, Lee K, Song J, Giedt RJ, Kim E, Kovach AE, Hochberg EP, Castro CM, Lee H, Weissleder R. On chip analysis of CNS lymphoma in cerebrospinal fluid. Theranostics 2015; 5:796-804. PubMed
  • Im H, Shao H, Park YI, Peterson VM, Castro CM, Weissleder R, Lee H. Label-free detection and molecular profiling of exosomes with a nano-plasmonic sensor. Nat Biotechnol 2014. PubMed
  • Ghazani AA, Pectasides M, Sharma A, Castro CM, Mino-Kenudson M, Lee H, Shepard JA, Weissleder R. Molecular characterization of scant lung tumor cells using iron-oxide nanoparticles and micro-nuclear magnetic resonance. 2014; 10:661-8. PubMed
  • Ullal AV, Peterson V, Agasti SS, Tuang S, Juric D, Castro CM, Weissleder R. Cancer cell profiling by barcoding allows multiplexed protein analysis in fine-needle aspirates. Sci Transl Med 2014; 6:219ra9. PubMed
  • Castro CM, Ghazani AA, Chung J, Shao H, Issadore D, Yoon TJ, Weissleder R, Lee H. Miniaturized nuclear magnetic resonance platform for detection and profiling of circulating tumor cells. Lab Chip 2013; 14:14-23. PubMed
  • Peterson VM, Castro CM, Chung J, Miller NC, Ullal AV, Castano MD, Penson RT, Lee H, Birrer MJ, Weissleder R. Ascites analysis by a microfluidic chip allows tumor-cell profiling. Proc Natl Acad Sci U S A 2013; 110:E4978-86. PubMed
  • Ghazani AA, McDermott S, Pectasides M, Sebas M, Mino-Kenudson M, Lee H, Weissleder R, Castro CM. Comparison of select cancer biomarkers in human circulating and bulk tumor cells using magnetic nanoparticles and a miniaturized micro-NMR system. 2013. PubMed
  • Keliher EJ, Reiner T, Earley S, Klubnick J, Tassa C, Lee AJ, Ramaswamy S, Bardeesy N, Hanahan D, Depinho RA, Castro CM, Weissleder R. Targeting cathepsin E in pancreatic cancer by a small molecule allows in vivo detection. Neoplasia 2013; 15:684-93. PubMed
  • Peterson VM, Castro CM, Lee H, Weissleder R. Orthogonal amplification of nanoparticles for improved diagnostic sensing. ACS Nano 2012. PubMed
  • Haun JB, Castro CM, Wang R, Peterson VM, Marinelli BS, Lee H, Weissleder R. Micro-NMR for rapid molecular analysis of human tumor samples. Sci Transl Med 2011; 3:71ra16. PubMed
  • Perez DL, Diamond EL, Castro CM, Diaz A, Buonanno F, Nogueira RG, Sheth K. Factor XIII deficiency related recurrent spontaneous intracerebral hemorrhage: a case and literature review. Clin Neurol Neurosurg 2011; 113:142-5. PubMed
Hide